Literature DB >> 27682885

Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China).

Xueli Yang1, Jianxin Li1, Dongsheng Hu1, Jichun Chen1, Ying Li1, Jianfeng Huang1, Xiaoqing Liu1, Fangchao Liu1, Jie Cao1, Chong Shen1, Ling Yu1, Fanghong Lu1, Xianping Wu1, Liancheng Zhao1, Xigui Wu1, Dongfeng Gu2.   

Abstract

BACKGROUND: The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of atherosclerotic cardiovascular disease (ASCVD). However, prediction models in common use were formulated primarily in white populations. The China-PAR project (Prediction for ASCVD Risk in China) is aimed at developing and validating 10-year risk prediction equations for ASCVD from 4 contemporary Chinese cohorts.
METHODS: Two prospective studies followed up together with a unified protocol were used as the derivation cohort to develop 10-year ASCVD risk equations in 21 320 Chinese participants. The external validation was evaluated in 2 independent Chinese cohorts with 14 123 and 70 838 participants. Furthermore, model performance was compared with the Pooled Cohort Equations reported in the American College of Cardiology/American Heart Association guideline.
RESULTS: Over 12 years of follow-up in the derivation cohort with 21 320 Chinese participants, 1048 subjects developed a first ASCVD event. Sex-specific equations had C statistics of 0.794 (95% confidence interval, 0.775-0.814) for men and 0.811 (95% confidence interval, 0.787-0.835) for women. The predicted rates were similar to the observed rates, as indicated by a calibration χ2 of 13.1 for men (P=0.16) and 12.8 for women (P=0.17). Good internal and external validations of our equations were achieved in subsequent analyses. Compared with the Chinese equations, the Pooled Cohort Equations had lower C statistics and much higher calibration χ2 values in men.
CONCLUSIONS: Our project developed effective tools with good performance for 10-year ASCVD risk prediction among a Chinese population that will help to improve the primary prevention and management of cardiovascular disease.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  assessment; atherosclerosis; cardiovascular diseases; risk; risk factors

Mesh:

Year:  2016        PMID: 27682885     DOI: 10.1161/CIRCULATIONAHA.116.022367

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  97 in total

Review 1.  A systematic review of the status and methodological considerations for estimating risk of first ever stroke in the general population.

Authors:  Wei Xu; Jiuyi Huang; Qingsong Yu; Hongfan Yu; Yang Pu; Qiuling Shi
Journal:  Neurol Sci       Date:  2021-03-30       Impact factor: 3.307

Review 2.  The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus.

Authors:  Yanglu Zhao; Nathan D Wong
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

3.  Cardiovascular Disease Risk Estimation in China.

Authors:  Paul K Whelton; Lisandro D Colantonio
Journal:  Ann Intern Med       Date:  2019-02-19       Impact factor: 25.391

4.  Chronic Effects of High Fine Particulate Matter Exposure on Lung Cancer in China.

Authors:  Jianxin Li; Xiangfeng Lu; Fangchao Liu; Fengchao Liang; Keyong Huang; Xueli Yang; Qingyang Xiao; Jichun Chen; Xiaoqing Liu; Jie Cao; Shufeng Chen; Chong Shen; Ling Yu; Fanghong Lu; Xianping Wu; Liancheng Zhao; Xigui Wu; Ying Li; Dongsheng Hu; Jianfeng Huang; Meng Zhu; Yang Liu; Hongbing Shen; Dongfeng Gu
Journal:  Am J Respir Crit Care Med       Date:  2020-12-01       Impact factor: 21.405

5.  Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.

Authors:  Yawen Jiang; Weiyi Ni
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

6.  Long-Term Exposure to Fine Particulate Matter and Hypertension Incidence in China.

Authors:  Keyong Huang; Xueli Yang; Fengchao Liang; Fangchao Liu; Jianxin Li; Qingyang Xiao; Jichun Chen; Xiaoqing Liu; Jie Cao; Chong Shen; Ling Yu; Fanghong Lu; Xianping Wu; Liancheng Zhao; Xigui Wu; Ying Li; Dongsheng Hu; Jianfeng Huang; Yang Liu; Xiangfeng Lu; Dongfeng Gu
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

7.  Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China.

Authors:  Zengwu Wang; Guang Hao; Xin Wang; Zuo Chen; Linfeng Zhang; Zugui Zhang; Hao Hu; William S Weintraub; Runlin Gao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-03       Impact factor: 3.738

8.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

Review 9.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

10.  Potassium selenocyanoacetate reduces the blood triacylglycerol and atherosclerotic plaques in high-fat-dieted mice.

Authors:  Shaoqin Liu; Fang Fang; Guanghui Fan
Journal:  Cardiovasc Diagn Ther       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.